Salmonella investigation leads to another kratom recall

UCM602561 280x210 Salmonella investigation leads to another kratom recallTamarack Inc., is recalling its Eclipse Kratom powder products because sample testing by federal authorities revealed the product was contaminated with Salmonella, an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. The testing was part of a multi-state Salmonella investigation linked to kratom products conducted by the Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and local and state health authorities.

At least 87 people in 35 states have become sickened with Salmonella after consuming kratom. Twenty-seven of those infected were hospitalized.

Tamarack has identified the suppler and source of the contaminated product and has ceased the production and distribution of the product.

Salmonella can be dangerous to weaker individuals, but healthy people who become infected can experience symptoms including fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e. infected aneurysms), endocarditis and arthritis.

Affected Eclipse Kratom products are packaged in plastic, heat-sealed pouches or plastic-sealed bottles sold in one-gram capsules and powder. About 120 units were distributed to five retailers in Utah. To date no illnesses linked to Eclipse Kratom have been reported.

Kratom is an herbal supplement that is classified as an opioid by the FDA because it can produce a sense of euphoria. The product is considered highly addictive.

Anyone who has affected Eclipse Kratom products in their possession are advised not to consume them and to return them to the place of purchase for a full refund. Retail stores will receive a full refund from Tamarack within 14 business days.

Any adverse events related to this recall should be reported to the FDA MedWatch Adverse Event Reporting Program at

FDA Recall Notice
Righting Injustice